

Drug Utilization Review (DUR) Meeting Minutes December 2, 2015

Members Present: Tanya Schmidt, Laura Schield, Katie Kram, Wendy Brown, Michael Quast, Russ Sobotta, Peter Woodrow, Andrea Honeyman, Jeffrey Hostetter, Carlotta McCleary, Michael Booth, Leneika Roehrich

Members Absent: James Carlson, Steve Irsfeld

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy, Gary Betting

W. Brown called the meeting to order at 1:00 p.m. Chair W. Brown asked for a motion to approve the minutes of the September meeting. T. Schmidt moved that the minutes be approved, and P. Woodrow seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

New member introduction

B. Joyce introduced Leneika Roehrich as a new pharmacist member appointed to the DUR Board.

Budget update

There are approximately 66,000 recipients currently enrolled in Medicaid with approximately 17,000 of these recipients receiving pharmacy benefits each month. The monthly drug spend is approximately \$1.5 million (net of rebates). Every week, approximately \$800,000 is paid to pharmacies for approximately 4,000 recipients obtaining 13,000 claims. The average cost per utilizer per month is around \$200 and the average prescription cost is around \$60.

Second reviews

A motion and second were made at the September meeting to place Marinol, inhaled corticosteroid/long-acting beta-2 agonists, medications used to treat IBS/OIC, medications used to treat ulcerative colitis, SGLT2 products, immediate release oxycodone, inhaled anti-infectives for cystic fibrosis, and leukotriene modifiers on prior authorization. The topics were brought up for a second review. Julie McDavitt and Jennifer Stoffel provided public comment. The motion to place these medications on prior authorization passed with one audible dissent for Marinol and no audible dissent for inhaled corticosteroid/long-acting beta-2 agonists, medications used to treat IBS/OIC, medications used to treat ulcerative colitis, SGLT2 products, immediate release oxycodone, inhaled anti-infectives for cystic fibrosis, and leukotriene modifiers.

Immediate release narcotics in conjunction with immediate release narcotic combinations review

A. Murphy shared with the Board that almost all of the immediate release narcotics used in conjunction with immediate release narcotic combinations is made up of tramadol + Percocet and tramadol + Norco. The remaining combinations were hydromorphone + Norco, oxycodone + Norco, and meperidine + Norco.

Cytokine modulators review

B. Joyce reviewed cytokine modulators with the Board. This class already has a prior authorization for indication. In the future, this class will be managed through the PDL and one product may be preferred over another. R. Troxell, representing Novartis, spoke.

Insulin review

B. Joyce reviewed insulin with the Board. A motion was made by J. Hostetter to allow the department to manage the class through prior authorization. The motion was seconded by M. Booth. There was no public comment. This topic will be reviewed at the next meeting.

Steroid inhalers review

B. Joyce reviewed steroid inhalers with the Board. A motion was made by M. Booth to allow the department to manage the class through prior authorization. The motion was seconded by M. Quast. Bradley Haas, representing AstraZeneca, spoke. This topic will be reviewed at the next meeting.

Digestive enzymes review

B. Joyce reviewed digestive enzymes with the Board. A motion was made by L. Schield to allow the department to manage the class through prior authorization. T. Schmidt seconded the motion. There was no public comment. This topic will be reviewed at the next meeting.

Nasal steroids review

B. Joyce reviewed nasal steroids with the Board. There was no public comment. J. Hostetter made a motion to allow the department to manage the class through prior authorization. M. Booth seconded the motion. This topic will be reviewed at the next meeting.

Otic anti-infectives review

B. Joyce reviewed otic anti-infectives with the Board. There was no public comment. K. Kram made a motion to allow the department to manage the class through prior authorization. P. Woodrow seconded the motion. This topic will be reviewed at the next meeting.

Ulcer anti-infectives review

B. Joyce reviewed ulcer anti-infectives with the Board. There was no public comment. T. Schmidt made a motion to allow the department to manage the class through prior authorization. L. Schield seconded the motion. This topic will be reviewed at the next meeting.

Criteria recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Hostetter moved to approve the new criteria and P. Woodrow seconded the motion. Chair W. Brown called for a voice vote. The motion passed with no audible dissent.

Annual prior authorization review

The Board reviewed all forms and criteria that have previously been placed on prior authorization. There was no public comment.

The next DUR Board meeting will be held March 2, 2016 in Bismarck. L. Schield made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. W. Brown adjourned the meeting.